A look at the strength of micro and macro EEG analysis for distinguishing insomnia within an HIV cohort.

Mark McIntosh,'s picture
PubMed URL: 
Salas RM
Author List: 
Gunnarsdottir KM
Kang YM
Kerr MS
Sarma SV
Ewen J
Allen R
Gamaldo C
Salas RM
Conf Proc IEEE Eng Med Biol Soc
PubMed ID: 
HIV patients are often plagued by sleep disorders and suffer from sleep deprivation. However, there remains a wide gap in our understanding of the relationship between HIV status, poor sleep, overall function and future outcomes; particularly in the case of HIV patients otherwise well controlled on cART (combined anti-retroviral therapy). In this study, we compared two groups: 16 non-HIV subjects (seronegative controls) and 12 seropositive HIV patients with undetectable viral loads. We looked at sleep behavioral (macro-sleep) features and sleep spectral (micro-sleep) features obtained from human-scored overnight EEG recordings to study whether the scored EEG data can be used to distinguish between controls and HIV subjects. Specifically, the macro-sleep features were defined by sleep stages and included sleep transitions, percentage of time spent in each sleep stage, and duration of time spent in each sleep stage. The micro-sleep features were obtained from the power spectrum of the EEG signals by computing the total power across all channels and frequencies, as well as the average power in each sleep stage and across different frequency bands. While the macro features do not distinguish between the two groups, there is a significant difference and a high classification accuracy for the scoring-independent micro features. This spectral separation is interesting because evidence suggests a relationship between sleep complaints and cognitive dysfunction in HIV patients stable on cART. Furthermore, there are currently no biomarkers that predict the early development of cognitive decline in HIV patients. Thus, a micro-sleep architectural approach could serve as a biomarker to identify HIV patients vulnerable to cognitive decline, providing an avenue to explore the utility of early intervention.
Published Date: 
January, 2015

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.

Learn more.

Appointments & Referrals



Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.


Resource Finder


A free resource that provides access to information and support for individuals and families living with developmental disabilities.